Pulmatrix (NASDAQ:PULM) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Trading Down 1.4 %

Shares of PULM stock opened at $2.09 on Tuesday. The firm has a fifty day moving average price of $1.84 and a 200 day moving average price of $1.88. The company has a market cap of $7.63 million, a P/E ratio of -0.54 and a beta of 0.92. Pulmatrix has a 12 month low of $1.55 and a 12 month high of $3.14.

Pulmatrix (NASDAQ:PULM) last issued its earnings results on Thursday, March 28th. The biotechnology company reported ($0.57) EPS for the quarter. The firm had revenue of $2.20 million for the quarter. Pulmatrix had a negative return on equity of 63.94% and a negative net margin of 193.49%.

Hedge Funds Weigh In On Pulmatrix

A number of institutional investors and hedge funds have recently modified their holdings of PULM. Vanguard Group Inc. lifted its position in Pulmatrix by 62.9% in the fourth quarter. Vanguard Group Inc. now owns 35,082 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 13,548 shares during the last quarter. Susquehanna International Group LLP purchased a new stake in Pulmatrix in the first quarter valued at $73,000. Mariner LLC purchased a new stake in Pulmatrix in the fourth quarter valued at $97,000. Citadel Advisors LLC purchased a new stake in Pulmatrix in the second quarter valued at $141,000. Finally, Renaissance Technologies LLC lifted its position in Pulmatrix by 7.3% in the second quarter. Renaissance Technologies LLC now owns 121,920 shares of the biotechnology company’s stock valued at $560,000 after acquiring an additional 8,300 shares during the last quarter. Institutional investors and hedge funds own 11.84% of the company’s stock.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.